vs
莫德纳（MRNA）与Rackspace Technology, Inc.（RXT）财务数据对比。点击上方公司名可切换其他公司
莫德纳的季度营收约是Rackspace Technology, Inc.的1.5倍（$1.0B vs $682.8M），Rackspace Technology, Inc.净利率更高（-4.8% vs -19.7%，领先14.9%），Rackspace Technology, Inc.同比增速更快（-0.4% vs -45.4%），Rackspace Technology, Inc.自由现金流更多（$56.0M vs $-880.0M），过去两年Rackspace Technology, Inc.的营收复合增速更高（-0.6% vs -45.0%）
莫德纳是一家总部位于美国马萨诸塞州剑桥市的生物制药企业，深耕RNA治疗领域，核心业务聚焦mRNA疫苗研发。其疫苗通过信使RNA（mRNA）分子拷贝传递蛋白合成指令以触发人体免疫反应，公司名称由“修饰”“RNA”与“现代”三个词组合而来。
Rackspace Technology, Inc.是总部位于美国得克萨斯州圣安东尼奥的云计算企业，在弗吉尼亚州雷斯顿以及澳大利亚、加拿大、英国、印度、迪拜、瑞士、荷兰、德国、新加坡、墨西哥、中国香港等多个国家和地区设有办事处，数据中心分布于全球多个主要城市，为客户提供专业的云计算相关服务。
MRNA vs RXT — 直观对比
营收规模更大
MRNA
是对方的1.5倍
$682.8M
营收增速更快
RXT
高出45.0%
-45.4%
净利率更高
RXT
高出14.9%
-19.7%
自由现金流更多
RXT
多$936.0M
$-880.0M
两年增速更快
RXT
近两年复合增速
-45.0%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.0B | $682.8M |
| 净利润 | $-200.0M | $-32.7M |
| 毛利率 | 79.6% | 17.6% |
| 营业利润率 | -25.6% | -0.5% |
| 净利率 | -19.7% | -4.8% |
| 营收同比 | -45.4% | -0.4% |
| 净利润同比 | -1638.5% | 41.6% |
| 每股收益（稀释后） | $-0.51 | $-0.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MRNARXT
| Q4 25 | — | $682.8M | ||
| Q3 25 | $1.0B | $671.2M | ||
| Q2 25 | — | $666.3M | ||
| Q1 25 | — | $665.4M | ||
| Q4 24 | $966.0M | $685.6M | ||
| Q3 24 | $1.9B | $675.8M | ||
| Q2 24 | — | $684.9M | ||
| Q1 24 | — | $690.8M |
净利润MRNARXT
| Q4 25 | — | $-32.7M | ||
| Q3 25 | $-200.0M | $-67.1M | ||
| Q2 25 | — | $-54.5M | ||
| Q1 25 | — | $-71.5M | ||
| Q4 24 | $-1.1B | $-56.0M | ||
| Q3 24 | $13.0M | $-186.6M | ||
| Q2 24 | — | $25.0M | ||
| Q1 24 | — | $-640.6M |
毛利率MRNARXT
| Q4 25 | — | 17.6% | ||
| Q3 25 | 79.6% | 19.4% | ||
| Q2 25 | — | 19.4% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | 23.5% | 19.2% | ||
| Q3 24 | 72.4% | 20.3% | ||
| Q2 24 | — | 19.2% | ||
| Q1 24 | — | 19.2% |
营业利润率MRNARXT
| Q4 25 | — | -0.5% | ||
| Q3 25 | -25.6% | -5.1% | ||
| Q2 25 | — | -3.8% | ||
| Q1 25 | — | -5.8% | ||
| Q4 24 | -129.0% | -4.2% | ||
| Q3 24 | -3.8% | -25.7% | ||
| Q2 24 | — | -7.9% | ||
| Q1 24 | — | -94.5% |
净利率MRNARXT
| Q4 25 | — | -4.8% | ||
| Q3 25 | -19.7% | -10.0% | ||
| Q2 25 | — | -8.2% | ||
| Q1 25 | — | -10.7% | ||
| Q4 24 | -115.9% | -8.2% | ||
| Q3 24 | 0.7% | -27.6% | ||
| Q2 24 | — | 3.7% | ||
| Q1 24 | — | -92.7% |
每股收益（稀释后）MRNARXT
| Q4 25 | — | $-0.13 | ||
| Q3 25 | $-0.51 | $-0.28 | ||
| Q2 25 | — | $-0.23 | ||
| Q1 25 | — | $-0.31 | ||
| Q4 24 | $-2.91 | $-0.20 | ||
| Q3 24 | $0.03 | $-0.82 | ||
| Q2 24 | — | $0.11 | ||
| Q1 24 | — | $-2.91 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.1B | $105.8M |
| 总债务越低越好 | — | $2.7B |
| 股东权益账面价值 | $9.3B | $-1.2B |
| 总资产 | $12.1B | $2.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资MRNARXT
| Q4 25 | — | $105.8M | ||
| Q3 25 | $1.1B | $99.5M | ||
| Q2 25 | — | $103.9M | ||
| Q1 25 | — | $128.0M | ||
| Q4 24 | $1.9B | $144.0M | ||
| Q3 24 | $1.6B | $157.1M | ||
| Q2 24 | — | $190.2M | ||
| Q1 24 | — | $282.6M |
总债务MRNARXT
| Q4 25 | — | $2.7B | ||
| Q3 25 | — | $2.8B | ||
| Q2 25 | — | $2.8B | ||
| Q1 25 | — | $2.8B | ||
| Q4 24 | — | $2.8B | ||
| Q3 24 | — | $2.8B | ||
| Q2 24 | — | $2.9B | ||
| Q1 24 | — | $3.0B |
股东权益MRNARXT
| Q4 25 | — | $-1.2B | ||
| Q3 25 | $9.3B | $-1.2B | ||
| Q2 25 | — | $-1.1B | ||
| Q1 25 | — | $-1.1B | ||
| Q4 24 | $10.9B | $-1.0B | ||
| Q3 24 | $11.9B | $-949.7M | ||
| Q2 24 | — | $-756.2M | ||
| Q1 24 | — | $-787.2M |
总资产MRNARXT
| Q4 25 | — | $2.8B | ||
| Q3 25 | $12.1B | $2.8B | ||
| Q2 25 | — | $2.9B | ||
| Q1 25 | — | $3.0B | ||
| Q4 24 | $14.1B | $3.1B | ||
| Q3 24 | $15.8B | $3.1B | ||
| Q2 24 | — | $3.4B | ||
| Q1 24 | — | $3.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-847.0M | $59.7M |
| 自由现金流经营现金流 - 资本支出 | $-880.0M | $56.0M |
| 自由现金流率自由现金流/营收 | -86.6% | 8.2% |
| 资本支出强度资本支出/营收 | 3.2% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-1.9B | $90.6M |
8季度趋势，按日历期对齐
经营现金流MRNARXT
| Q4 25 | — | $59.7M | ||
| Q3 25 | $-847.0M | $70.7M | ||
| Q2 25 | — | $8.4M | ||
| Q1 25 | — | $12.6M | ||
| Q4 24 | $825.0M | $54.3M | ||
| Q3 24 | $-1.6B | $51.8M | ||
| Q2 24 | — | $24.1M | ||
| Q1 24 | — | $-90.3M |
自由现金流MRNARXT
| Q4 25 | — | $56.0M | ||
| Q3 25 | $-880.0M | $42.7M | ||
| Q2 25 | — | $-12.4M | ||
| Q1 25 | — | $4.3M | ||
| Q4 24 | $303.0M | $34.4M | ||
| Q3 24 | $-1.7B | $27.3M | ||
| Q2 24 | — | $-14.5M | ||
| Q1 24 | — | $-118.4M |
自由现金流率MRNARXT
| Q4 25 | — | 8.2% | ||
| Q3 25 | -86.6% | 6.4% | ||
| Q2 25 | — | -1.9% | ||
| Q1 25 | — | 0.6% | ||
| Q4 24 | 31.4% | 5.0% | ||
| Q3 24 | -92.2% | 4.0% | ||
| Q2 24 | — | -2.1% | ||
| Q1 24 | — | -17.1% |
资本支出强度MRNARXT
| Q4 25 | — | 0.5% | ||
| Q3 25 | 3.2% | 4.2% | ||
| Q2 25 | — | 3.1% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | 54.0% | 2.9% | ||
| Q3 24 | 8.1% | 3.6% | ||
| Q2 24 | — | 5.6% | ||
| Q1 24 | — | 4.1% |
现金转化率MRNARXT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -120.46× | — | ||
| Q2 24 | — | 0.96× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MRNA
| COVID19 | $971.0M | 96% |
| Other Revenue | $20.0M | 2% |
| Grant | $14.0M | 1% |
| Collaboration Arrangement Including Arrangements With Affiliate | $7.0M | 1% |
| License And Royalty | $2.0M | 0% |
RXT
| Public Cloud Services Segment | $442.2M | 65% |
| Private Cloud Service Segment | $240.6M | 35% |
